Tag: Motley Fool

The E2 Metals Ltd (ASX: E2M) share price entered the stratosphere today. This comes after the company discovered significant gold and silver mineralisation at the company’s Conserrat project in Argentina.

At Monday’s closing bell, the Australian exploration and development company’s shares finished 47.92% higher to 35.5 cents.

E2 Metals locates new gold

According to its statement, E2 Metals reported gold and silver assay results at Andrea Sur, the western extension of Conserrat in Argentina’s Santa Cruz province.

Two shallow Reverse Circulation (RC) drill holes were completed on two sections spaced 120 metres apart. The results included the following:

• 16 metres at 15 grams per tonne (gpt) of gold (Au) and 22gpt of silver (Ag) from 31 metres (drill hole CORC-183); and
• 4 metres at 3gpt Au and 11gpt Ag from 29 metres (drill hole CORC-190).

The drilling was designed to test beneath a float train of epithermal vein boulders extending for over a 150-metre strike.

Notably, mineralisation is open in all directions and can be traced over 1200 metres in gradient array induced polarization (IP) geophysical images. This is a geophysical method used in mineral exploration and mine operations in a bid to find new discoveries throughout the resource area.

E2 Metals will prioritise follow-up drilling along the strike range of drill hole CORC-183. In addition, scout drilling will commence along the host structure on sections spaced 100 metres away from each other.

E2 Metals managing director Todd Williams commented:

The discovery of high-grade mineralisation at Andrea Sur is important for two reasons:

Firstly, it is the westernmost discovery made to date at the Conserrat project, significantly expanding the footprint of this emerging gold and silver district.

Secondly, it turns a spotlight on adjacent structures that have never been drill tested, such as Andrea, a prospect that is host to a prominent silica alteration cap geologically similar to those that overly mineralised epithermal veins elsewhere in the Deseado Massif, such as Newmont’s Silica Cap deposit at Cerro Negro.

About the E2 Metals

Despite today’s gains, E2 Metals shares have tracked almost 60% lower over the past 12 months. When looking at year-to-date, its shares have given up around 40%.

On valuation grounds, E2 Metals commands a market capitalisation of roughly $53.42 million, with approximately 150.47 million shares on issue.

The post Here’s why the E2 Metals (ASX:E2M) share price exploded 48% today appeared first on The Motley Fool Australia.

More reading

• RareX (ASX:REE) share price bounds 21% on “world-class” intercept
• Why is the Lovisa (ASX:LOV) share price tarnishing today?
• Nuix (ASX:NXL)’s own shareholders are suing it
• Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough
• Here are the top 10 ASX shares today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3cDsPy5

Shares in rare earths company RareX Ltd (ASX: REE) charged higher today, finishing 21% in the green. Investors were piling into RareX shares following a company announcement on its Cummins rare earths project.

RareX advised of results from a recent drilling program at the Cummins site where it is exploring for rare earths minerals.

The RareX share price traded as high as 12.5 cents today before cooling off in afternoon trading to finish at 11.5 cents.

Here are the details out of the rare earth miner’s camp.

What did RareX announce?

The company advised it had come into “exceptional high-grade intercepts of up to 10.6% TREO [total rare earth oxides] in [the] primary zone at Cummins Range Rare Earths Project”.

These assays include a “world-class intercept of 102.9m at 1.6% TREO with more assays to come”.

Results were received from RareX’s diamond drilling program at the Cummins Project, located in the Kimberly region in WA.

The results provide evidence the primary zone potentially contains high-grade mineralisation “reinforcing the opportunity to substantially increase the current mineral resource at the site”.

RareX notes that diamond core drilling has significantly advanced the geological understanding of the Cummins Range deposit and continues to deliver high-grade rare earths and niobium mineralisation.

The drilling of multiple new zones in the hanging wall and footwall to new depths is “very exciting”, according to the company, and “shallow wide rare earths and niobium intercepts in the breccia zone is even better”.

This breccia zone has consistent wide intervals of 1% to 2% TREO and strong niobium mineralisation as shown in other drill holes in this zone.

Speaking on the announcement, RareX managing director Jeremy Robinson said:

These exceptional results are a game-changer for Cummins Range. The diamond drilling completed towards the end of the year has been geared towards unlocking the potential of the primary zone and showing that we have a potentially much larger and higher grade project on our hands here. These results strongly vindicate that belief.

Robinson continued:

Partial assays from CDX0011 have returned some of the highest grades ever recorded at Cummins Range, including a fantastically high-grade zone grading 10.6% TREO – rarely seen in deposits like this. Plus, we have a world-class 103 metre intercept in hole CDX0004, in an area where previous explorers believed the mineralization had been upgraded by weathering processes. Instead, we have a very large zone of primary mineralization, which is a very exciting development for the Project.

RareX share price snapshot

In the past 12 months, the RareX share price has fallen 8% into the red, underperforming the benchmark index.

Looking year to date, RareX shares are flat. However, they have climbed 15% in the last month.

The post RareX (ASX:REE) share price bounds 21% on “world-class” intercept appeared first on The Motley Fool Australia.

More reading

• Why is the Lovisa (ASX:LOV) share price tarnishing today?
• Nuix (ASX:NXL)’s own shareholders are suing it
• Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough
• Here are the top 10 ASX shares today
• The Beach Energy (ASX:BPT) share price has lost 15% so far this month. What’s happening?

The author Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3DGHFje

The Lovisa Holdings Ltd (ASX: LOV) share price is down around 3% after the affordable jewellery business announced a trading update to the market.

It gave this update before its annual general meeting (AGM).

This announcement focused on the company’s store network and current trading conditions.

Lovisa’s sales recovery

Lovisa said that its global comparable store sales for the first 20 weeks of FY22, which continued its strong trajectory and were up 25.2% on FY21, with total sales for the period up 46.1% on FY21 despite the impacts of the lockdowns in Australia, Malaysia and New Zealand.

The comparable store sales are measured based on stores open and able to trade. Ones that are closed because of the government restrictions are not included.

The strength of the sales growth could be an important factor for the Lovisa share price.

Store count and status

Lovisa said that there are currently 570 stores in the global store network, with 31 new stores opened since the end of FY21 and five closures.

It has now been able to open all the stores in its network and have been able to re-open all stores in its network that had been temporarily closed in Victoria, New South Wales, Malaysia and New Zealand back to trading.

However, stores in Austria have now moved into lockdown and the three stores there have been closed.

Lovisa also noted that it has two new franchise stores in Cyprus, bringing its geographical coverage to 21 countries globally.

Outlook for Lovisa

Management’s outlook can have an impact on investor thoughts on the valuation and Lovisa share price.

Lovisa said that despite the disruptions that the business continues to face globally, management are pleased with the way the business has performed and remain focused on continuing to drive it store rollout.

However, the company did have a somewhat negative comment regarding its store rollout. Lovisa said:

Whilst we are pleased with the pipeline of opportunities we have available, our store rollout for the year to date has been slower than we would like as a result of logistics delays and shortages of store build contractors in key growth markets.

Whilst we are managing this closely, it may continue to cause rollout delays in the short term as well as increases in the cost of store builds. We also continue to face the same challenges in relation to freight costs that we have previously noted, with reduced global freight capacity still impacting on pricing.

Victor Herrero has now formally commenced the role of CEO and has previous experience in growing businesses into countries like China and India, which are large markets that Lovisa might be interested about growing in.

The post Why is the Lovisa (ASX:LOV) share price tarnishing today? appeared first on The Motley Fool Australia.

More reading

• Top brokers name 3 ASX shares to buy next week
• Why Calix, Imugene, Legacy Iron Ore, and Lovisa shares are charging higher
• Lovisa (ASX:LOV) share price surges to record high after Macquarie upgrade
• These were the 5 best performing ASX retail shares in October
• 2 impressive ASX shares that could be buys in November 2021

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3oSE3ED

Devastated shareholders of Nuix Ltd (ASX: NXL) have had enough, launching a class action against the software company this week.

Legal firm Shine Lawyers announced Monday that their case has been filed in the Supreme Court of Victoria, alleging Nuix gave “inadequate guidance” on revenue and “misleading” sales forecasts.

The shareholders are also accusing the company they own of breaching its continuous disclosure obligations as a publicly listed entity.

Nuix shares listed on the ASX last December with much hype after an initial public offer price of $5.31. Investor fervour hit its peak in January, with the stock price reaching $11.86.

But since then a series of governance scandals and financial downgrades have seen the stock plummet to a low of $2.16. 

Nuix shares closed Monday at $2.75, which was 1.43% down for the day. 

Nuix accused of costing investors “hundreds of millions of dollars”

Shine Lawyers class actions practice leader Craig Allsopp said its investigations uncovered the prospectus could have “misrepresented or omitted financial information and potential risks, which was misleading and deceptive to investors”.

“This inflated forecast has ultimately cost shareholders hundreds of millions of dollars,” he said.

“Our class action aims to recover these losses for the thousands of investors impacted by Nuix Limited’s alleged misconduct.”

The analytics software company on Monday acknowledged to the ASX that the class action had been filed against it.

“The claim does not identify the amount of any damages sought,” the statement read.

“Nuix disputes the allegations and will be defending the claim.”

Allsopp encouraged any investors who bought Nuix shares between 18 November 2020 and 30 May 2021 to register for the lawsuit.

Nuix last month appointed a new chief executive and chief financial officer, calling it an “important moment” in its history. 

Whether that provides a clean slate for investors remains to be seen.

Shaw and Partners senior investment adviser Adam Dawes said last week that he would wait until seeing the annual general meeting on 30 November before deciding whether the stock was a bargain buy.

“The shareholders are going to get those rotten tomatoes and get ready to throw them because there’s going to be some hard questions to be answered,” he told Switzer TV Investing.

“Even if it gets to $3 to $5 and I miss out on that initial rally, I’m comfortable then to get in because I know that some of these problems have been worked through.”

The post Nuix (ASX:NXL)’s own shareholders are suing it appeared first on The Motley Fool Australia.

More reading

• ASX 200 tech shares in focus as Nasdaq plunges 1.7%
• Are these 2 beaten-up ASX tech shares now bargain buys?
• Why are ASX 200 tech shares having such a lousy day?
• These were the best performing ASX tech shares in October
• These were the best performing ASX 200 shares last week

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Nuix Pty Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3FBgYNh

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) jumped higher today and finished 13% in the green.

Investors bid up the Race Oncology share price following study readouts for its lead drug candidate, Zantrene, in a heart safety research program.

Race Oncology shares traded as high as $3.83 before reversing course and finishing the day slightly lower at $3.81.

Here are the details.

What sent Race Oncology shares racing higher?

Race’s shares started well after it announced the company’s lead drug candidate, Zantrene, showed promising results in a recent preclinical trial.

The research found that Zantrene is able to “protect heart muscles cells from anthracycline (specifically doxorubicin) induced cell death while improving the killing of breast cancer cells”.

Anthracyclines are one of the most effective anti-cancer treatments developed and are used in more cancer settings than any other class of chemotherapeutic agent, according to the announcement.

However, whilst they are highly effective anti-cancer drugs, their use in patients comes with the serious risk of permanent damage to the heart.

Race’s discovery is therefore a step in resolving this issue for patients receiving life saving treatments in this complex area.

The discovery is to be fast-tracked to the clinic with a Phase 2b trial planned for 2022. The cohort will be made from breast cancer patients identified at risk of anthracycline-caused heart damage.

The company is also positive about where these latest results will lead in terms of Zantrene’s commercial success. It reckons the results “offer the potential of outsized clinical and commercial returns from new Zantrene/anthracycline formulations and combinations”.

Speaking on the announcement, Race Oncology’s CEO Phillip Lynch said:

Zantrene’s cardio toxic properties were always of interest, but this novel cardio protective insight is far more significant to the drug’s potential application as an adjunctive to anthracycline backbone chemotherapy. I look forward to the team quickly advancing these investigations so we might assess and progress this opportunity as a matter of substantial priority.

Chief Scientific Officer, Dr Daniel Tillett said:

After the discovery that Zantrene is a potent FTO inhibitor, this is a second ‘once in a lifetime’ discovery. To find that Zantrene can protect the heart from chemotherapy while also killing cancers better is an extraordinary ‘best of both worlds’ outcome. Given anthracyclines are used in millions of cancer patients every year, it is hard to overstate the clinical and commercial potential of this breakthrough.

Race Oncology share price history

In the past 12 months, the Race Oncology share price has gained 172% after rallying 118% this year to date.

It has soared 20% in the past month alone and is up 17% in the past week of trading as well. Each of these results outpaces the benchmark S&P/ASX 200 Index (ASX: XJO)’s gain of around 12.5% in the last year.

The post Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough appeared first on The Motley Fool Australia.

More reading

• Why the Race Oncology (ASX:RAC) share price is up on Monday
• Race Oncology (ASX:RAC) share price struggles despite new Leukemia study

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3DFGRet

Today, the S&P/ASX 200 Index (ASX: XJO) slipped lower following reports of a jump in COVID-19 cases across the US and Europe. At the end of the day, the benchmark index fell 0.59% to 7,353.1 points.

A change in sentiment on the back of rising COVID-19 case numbers dragged on ASX shares today. Tech and energy companies fared the worst, compounded by a fall in oil prices overnight for oil and gas shares. In addition, the big four banks held the index under on Monday.

However, the question is: which shares delivered the biggest returns to investors on the ASX today? Here are the ten stocks that rose to the occasion:

Top 10 ASX shares countdown today

Looking at the top 200 listed companies, Nickel Mines Ltd (ASX: NIC) was the biggest gainer today. Shares in the nickel mining company rallied 7.98% following news it entered into a memorandum of understanding with Chinese company Shanghai Decent. Find out more about Nickel Mines here.

The next biggest gaining ASX share today was Pilbara Minerals Ltd (ASX: PLS). Shares in the lithium producer increased by 4.45%. Despite the solid performance, there were no new announcements out from the company today. Uncover the latest Pilbara Minerals details here.

Today’s top 10 biggest gains were made in these ASX shares:

ASX-listed company	Share price	Price change
Nickel Mines Ltd (ASX: NIC)	$1.285	7.98%
Pilbara Minerals Ltd (ASX: PLS)	$2.465	4.45%
Orocobre Ltd (ASX: ORE)	$9.50	4.28%
Lynas Rare Earths Ltd (ASX: LYC)	$8.56	3.63%
Liberty Financial Group (ASX: LFG)	$6.00	2.74%
Champion Iron Ltd (ASX: CIA)	$4.22	2.68%
AMP Ltd (ASX: AMP)	$1.165	2.64%
Fortescue Metals Group Ltd (ASX: FMG)	$15.84	2.39%
South32 Ltd (ASX: S32)	$3.59	2.28%
AGL Energy Ltd (ASX: AGL)	$5.24	2.14%

Our top 10 ASX shares today countdown is a recurring end-of-day summary to ensure you know which companies were making big moves on the day. Check-in at Fool.com.au after the market has closed during weekdays to see which stocks make the countdown.

The post Here are the top 10 ASX shares today appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are topping the volume charts on Monday
• Why is the Northern Star (ASX:NST) share price sinking 3% today?
• Leading brokers name 3 ASX shares to buy today
• The Woolworths (ASX:WOW) share price is up 20% so far in 2021. Here’s why
• Here’s why ASX 200 travel shares are getting hammered today

Motley Fool contributor Mitchell Lawler owns shares of Lynas Corporation Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3HFt5e9

The Beach Energy Ltd (ASX: BPT) share price has continued to weaken in November. Shares in the oil and gas company have fallen 15% in value since the beginning of the month.

By the end of Monday’s session, the Beach Energy share price had declined to $1.20, 3.6% lower than its previous close. With no announcements out from the energy company today, we turn to broader events in the oil and gas industry.

Let’s unpack what might have weighed on investor sentiment.

Beach Energy share price hit by falling oil price

While the S&P/ASX 200 Index (ASX: XJO) was in negative territory on Monday, it was a worse sight for the energy sector. The benchmark index finished 0.5% lower, which is disappointing for investors. However, the energy sector slid 1.6%, leaving ASX-listed energy share investors out to dry.

Out of the bunch, the Beach Energy share price was the worst-performing energy company in the index. Following close behind was Woodside Petroleum Limited (ASX: WPL), Santos Ltd (ASX: STO), and Oil Search Ltd (ASX: OSH).

A falling oil price overnight was to blame for the catalyst behind the sector’s dismal performance to commence the week. According to Bloomberg, the WTI crude oil price fell 3.15% to US$75.94 a barrel. Meanwhile, the Brent crude oil price slipped 2.9% to US$78.89 a barrel.

Although, in the last month Beach Energy has been contending with more than just weakening oil prices. The dispropriate negative performance compared to its peers might stem from a couple of unsettling events this month.

Firstly, rumours were flying on 9 November 2021 of a potential exit of the company’s largest shareholder, Seven Group Holdings Ltd (ASX: SVW). These have since been refuted by Beach Energy’s chair Glenn Davis at the latest annual general meeting.

Secondly, a sudden transition of management might have the market on alert. The chief executive, Matt Kay, tendered his resignation at the beginning of the month. The role has since been temporarily filled with the appointment of Morné Engelbrecht as acting CEO.

These events combined likely have introduced increased volatility to the Beach Energy share price.

The post The Beach Energy (ASX:BPT) share price has lost 15% so far this month. What’s happening? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• 5 things to watch on the ASX 200 on Tuesday
• Why is the Beach Energy (ASX:BPT) share price continuing to slide on Wednesday?
• 5 things to watch on the ASX 200 on Wednesday
• Beach Energy (ASX:BPT) share price dips amid news Seven may dump 30% holding

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/30IHAxm

In many ways, 2021 can be called the year of the iron ore price. Much of the talk of the ASX town this year has revolved around this key economic metric driving the Australian economy. As we all know, mining plays a major role in our economic machine. Movements in the iron ore price, in particular, can have far-reaching consequences on everything from our exchange rate to the budgets our governments run.

So it was with much excitement that a record high iron ore price that reached more than US$200 a tonne earlier this year was received. That sent the share prices of the ASX’s biggest iron miners like BHP Group Ltd (ASX: BHP), Fortescue Metals Group Limited (ASX: FMG) and Rio Tinto Limited (ASX: RIO) to new all-time highs just a few months ago.

But equally momentous was the subsequent collapse the iron ore price has suffered through in the months since. The ‘red dirt’ was fetching as high as US$220 a tonne just a few months ago. But, today, it is asking just US$92.60 a tonne.

So if you were wondering why the Fortescue share price has now lost roughly 40% since late July, that’s probably a pretty good explanation.

As such, many investors might be wondering ‘where to from here?’ and hoping for an iron ore price forecast.

Ellison gives iron ore price forecast

Chriss Ellison is the executive chair of Mineral Resources Ltd (ASX: MIN), a mining and services company that has done exceptionally well over the past year (up around 35.5%). So it goes without saying that this is a man to get a decent iron ore price forecast from, if there is such a thing.

According to recent reporting in the Australian Financial Review (AFR), Mr Ellison is pushing ahead with his company’s expansion plans for iron ore, despite the recent price collapse. Ellison reportedly is expecting the iron ore price to “consolidate around US$100 a tonne”. Despite the distance between that price and the highs we saw earlier this year, this would still mean “handy margins” for a smaller player like Mineral Resources.

Ellison isn’t the only one looking at US$100 iron ore. The report also quotes Glyn Lawcock, of Barranjoey Capital Partners. Mr Lawcock is expecting the iron ore price to average “above US$100” in 2022. He points to what he sees as the potential for higher Chinese steel output once the 2022 Winter Olympics finish in Beijing next year.

So, if these experts are to be believed, the days of US$200-plus iron ore are over, at least for now. But they also clearly aren’t of the opinion that there isn’t still money to be made from the iron ore price.

The post Why this mining analyst is upbeat on the iron ore price forecast appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Fortescue’s push to axe diesel subsidies could cost ASX miners billions
• Why has the Rio Tinto (ASX:RIO) share price fallen in a hole over the past month?
• Top brokers name 3 ASX shares to buy next week
• Top brokers name 3 ASX shares to sell next week

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3xaD7yX

The Medibank Private Limited (ASX: MPL) share price has gone up by 8% in this month alone. What could be impacting the sentiment about the private health insurer?

Medibank shares have been somewhat variable in recent months. It has gone up by 16% over the last six months and 8% this month. But it’s only back to where it was during September 2021.

Just last week, the company held its annual general meeting (AGM) and gave a presentation.

Medibank AGM update

The company reminded investors that COVID has put health at the top of the community’s mind. In FY21, it experienced “solid financial performance”, “strong policyholder growth, an increase in market share and record customer advocacy.”

It saw health insurance operating profit growth of 14.4%, with Medibank Health segment profit rising by 12.9%. This helped overall group net profit after tax increasing 39.8% to $441.2 million. That included investment income being $117 million above last year.

Medibank said that it’s focused on scaling and expanding its preventative health programs. It invested in Myhealth Medical Group of GP clinics this year, to support expanding the footprint and transforming the approach to providing preventative healthcare for patients.

In the longer-term, its focus on preventative health will be “key” to help ensure the overall sustainability of the health system.

FY22 and outlook comments

The outlook can have impacts on the Medibank share price.

Medibank said that it remains committed to returning any permanent net claims savings due to COVID back to customers and it expects to confirm its next wave of customer support before the “end of the year”.

One comment that investors may be focusing on is that Medibank has seen “strong policyholder growth” continue in the first four months of FY22, with another 21,000 policyholders added.

Medibank said it expects industry participation growth will be slower in FY22 compared to FY21, so it’s now aiming to achieve growth of at least 3%, including growth in the Medibank brand.

Taking into account the recent COVID lockdowns in Victoria and NSW, on an underlying basis, it’s expecting average net claims per policy unit to be in line with the second half of FY21, or 2.4% among resident policyholders.

The business also believes that it can cut $15 million of health insurance management expenses to improve productivity in FY22. It’s also targeting “inorganic” growth for Medibank Health and health insurance.

Is the Medibank share price a buy now?

Some brokers think so, though the price target doesn’t leave a lot of gains on the table.

The broker Morgan Stanley currently thinks that Medibank shares are a buy with a price target of $3.80 – that’s a potential upside of around 5% over the next 12 months.

There are several brokers that rate Medibank as a hold, such as Ord Minnett, which has a price target of $3.30.

The post Why has the Medibank (ASX:MPL) share price leapt 8% in November so far? appeared first on The Motley Fool Australia.

More reading

• Here’s how the Medibank (ASX:MPL) share price has performed against the ASX200 in the last 3 months
• Why is the Medibank (ASX:MPL) share price underperforming NIB (ASX:NHF) lately?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3xa9EoO

If you have room for a new addition (or two) to your portfolio, then it could be worth checking out the shares listed below.

These shares come from very different areas of the market. But one thing they share in common, is that they are highly rated by analysts. Here’s what you need to know about them:

Life360 Inc (ASX: 360)

Life360 could be a quality option for ASX investors. It is the technology company responsible for the Life360 app.

This is the world’s leading real time, location-sharing app used by families across the world to stay safe and communicate. Its features include driver safety, messaging, and geo-fencing.

The company currently boasts a whopping 33.8 million monthly active users. And while this is generating significant recurring revenues for Life360, it is still only really in the early stages of monetising its massive user base.

The team at Bell Potter is very positive on Life360’s future. Its analysts see significant cross selling and upselling opportunities for the company in the future.

Because of this and its belief that its shares are cheap in comparison to peers, the recently retained its buy rating and lifted its price target to $14.75.

Orocobre Limited (ASX: ORE)

Orocobre could be another ASX share to buy. Following its recent merger with Galaxy Resources, it has become a top five global lithium mining company with a collection of high-quality assets. These include Olaroz, Mt Cattlin, and the Sal de Vida brine project.

Thanks to the clean energy transition and the rapid adoption of electric vehicles, Orocobre appears well-positioned to benefit greatly from increasing demand for battery making ingredients.

The team at Macquarie is very positive on Orocobre. The broker currently has a buy rating and $12.00 price target on its shares.

The post 2 excellent ASX shares brokers love appeared first on The Motley Fool Australia.

More reading

• ASX 200 (ASX:XJO) midday update: Lithium miners jump, Flight Centre tumbles
• 2 top ASX shares to buy according to WAM
• ASX 200 (ASX:XJO) midday update: Crown jumps, WiseTech tumbles
• 3 ASX shares getting analysts very excited
• Is the Orocobre (ASX:ORE) share price about to charge up?

Motley Fool contributor James Mickleboro owns shares of Orocobre Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Life360, Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3l027Ee